Gilead Sciences (NASDAQ: GILD) and the U.S. government have settled a billion-dollar patent dispute over Gilead’s HIV prevention drugs Truvada
12 months ago
On Thursday, Gilead Sciences (NASDAQ: GILD) said it has appointed Sanofi’s (NASDAQ: SNY) Dietmar Berger as its chief medical officer,
1 year ago
Gilead Sciences (NASDAQ: GILD) reported third-quarter financial results that handily beat Wall Street expectations on Wednesday as sales climbed 7%,
Shares of Gilead Sciences (NASDAQ: GILD) plunged by almost 10% on Monday following the disappointing outcome of a lung cancer
2 years ago
